Roche reported strong mid-stage weight‑loss data for a dual GLP‑1/GIP receptor agonist and is preparing Phase 3 studies after patients in a near‑year trial achieved clinically meaningful weight reductions. Separately, Roche said a GLP‑1/GIP candidate from Carmot produced 22.5% placebo‑adjusted weight loss at 48 weeks, underpinning Roche’s decision to escalate its obesity portfolio. The readouts validate Roche’s late‑stage investment in incretin biology and add competitive pressure to existing GLP‑1 incumbents. Roche’s progression to Phase 3 will expand the field of dual-agonists and intensify competition in regulatory filings and payer negotiations.